Skip to main content

Table 2 The comparison of the clinical features of survivors and the non-survivors

From: Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan

  Survivors Non-survivors p-value
Patients 71 138  
Age, years 69.3 ± 10.2 73.8 ± 8.8 0.002
Male 56 (78.9) 116 (84.1) 0.352
BMI, kg/m2 22.2 ± 3.9 22.3 ± 3.8 0.795
Brinkman Index    
 0/1–800/>800 26/14/25 42/31/46 0.719
F, H-J Classification scale    
 1/2/3/4/5 1/3/3/16/42 1/1/4/12/83 0.012
Specialty hospital care 60 (84.5) 113 (81.9) 0.634
Ambulance transfer 32 (45.1) 69 (50.0) 0.499
Performing bronchoscopy 14 (19.7) 6 (4.4) <0.001
Treatment regimen use    
 Sivelestat 37 (52.1) 67 (48.9) 0.626
 Diuretic drug 37 (52.1) 65 (47.1) 0.492
 Anticoagulant therapy 37 (52.1) 50 (36.2) 0.027
 Immunosuppressive therapy 30 (42.3) 45 (32.6) 0.169
 Intravenous high-dose cyclophosphamide 9 (12.7) 23 (16.7) 0.448
 PMX 4 (5.6) 9 (6.5) 0.801
 Recombinant human soluble thrombomodulin 3 (4.2) 6 (4.4) 0.967
 Antibiotic therapy 71 (100) 135 (97.8) 0.211
  β-Lactams 60 (84.5) 116 (84.1) 0.933
  Co-trimoxazole 56 (78.9) 59 (42.8) <0.001
  Quinolones 38 (53.5) 65 (47.1) 0.379
  Macrolides 23 (32.4) 25 (18.1) 0.020
  Tetracycline 6 (8.5) 12 (8.7) 0.952
  Anti-MRSA antibiotics 6 (8.5) 11 (7.8) 0.904
  Clindamycin 3 (4.2) 2 (1.5) 0.214
  Aminoglycoside 2 (2.8) 1 (0.7) 0.228
  Others 5 (7.0) 7 (5.1) 0.562
  1. Data are presented as mean ± SD or n (%), unless otherwise indicated. Definition of abbreviations: BMI = Body Mass Index, F, H-J = Fletcher, Hugh-Jones, PMX = Direct hemoperfusion with polymyxin B-immobilized fiber, MRSA = Methicillin-resistant Staphylococcus aureus. The total dose was not equal to 209 because there were missing values in the data file